News & Updates

Treatment with dupilumab significantly improves histologic and endoscopic measures of eosinophilic esophagitis (EoE) in young children aged 1–11 years, according to the phase III EoE KIDS trial presented at ESPGHAN 2023.

An elevated proportion of children and adolescents around the world, particularly girls or those with high BMI, experience disordered eating as shown in a meta-analysis of 32 studies from 16 countries.

A case-control surveillance study has found no link between monovalent COVID-19 boosters and miscarriage before 20 weeks of pregnancy.

Adding the probiotic Limosilactobacillus reuteri (L. reuteri) DSM 17938 to antibiotic therapy significantly reduced the incidence of antibiotic-associated diarrhoea (AAD) in children with acute otitis media or acute bacterial sinusitis in the PEARL study presented at ESPGHAN 2023.

Interim results from the ongoing Study 306, a phase III open-label trial, show improved immunogenicity and safety of the bivalent Omicron-containing mRNA-1273.214 vaccine in children 6 months to 5 years of age, both as a primary series and a booster.

Treatment with teduglutide for 48 weeks results in increased intestinal absorption and decreased parenteral nutrition (PN) dependency in children with short bowel syndrome (SBS)-related intestinal failure (IF), as shown in a study.

Children and adolescents with better cardiorespiratory endurance appear to have a reduced risk of inflammatory bowel disease (IBD), as shown in a study.